Overview

A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

Status:
Not yet recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN)

Phase:

Phase 2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.